Frustration Over English Funding Rejection For Zytiga And A Win For Ledaga
Zyntiga Decision 'Highlights Need For Innovative Pricing Models'
Executive Summary
Janssen and UK health technology assessment body NICE are being urged to sit down together and agree a suitable price for using Zytiga as a first-line treatment for advanced prostate cancer.